2 not yet recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Metastatic Hormone-Sensitive Prostate Cance: new trials by email Literature Review of Metastatic Hormone-Sensitive Prostate Cance trials Research Report on Metastatic Hormone-Sensitive Prostate Cance
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer Ra223, Darolutamide Oral Tablet, Androgen Deprivation Therapy (ADT) - Metastatic Hormone-Sensitive Prostate Cance | Phase 2 | Not yet recruiting | Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD | 50 | 2026-09-01 | 2026-07-21 |
| A Novel Insight Into CRPC Progression and Immune: Evidence From Single-cell Spatial Transcriptome Multi-omics Abiraterone + ADT - Metastatic Hormone-Sensitive Prostate Cance | Not yet recruiting | Anhui Medical University | 396 | 2025-09-01 | 2025-09-04 |
Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Prostatic Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1)
Androgen Antagonists (2) · Radium-223 (1) · abiraterone (1) · darolutamide (1)
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD (1) · Anhui Medical University (1)
Spain (1)
David Lorente, M.D., Ph.D. (1) · Guillermo de Velasco, M.D., Ph.D. (1)